share_log

华东医药获中国银河推荐评级,Q2业绩超预期,创新板块亮点频现

JRJ Finance ·  Aug 18 23:27  · Ratings

2024年8月18日,华东医药获中国银河推荐评级,近一个月华东医药获得6份研报关注。

研报预计华东医药2024-2026年归母净利润为34.29/39.95/46.06亿元,同比增长20.78%/16.52%/15.29%。研报认为,公司医药工业、医美以及工业微生物等板块经营保持稳健,创新转型为公司中长期发展提供想象空间。

风险提示:市场竞争的风险,市场推广不及预期的风险,新品研发不及预期的风险。

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment